Merck tests Next-Gen pneumonia shot in early human trial
NCT ID NCT07168915
Summary
This early-stage study is testing the safety and immune response of a new vaccine called V118E, designed to protect against illnesses caused by pneumonia bacteria. Researchers will enroll 126 healthy adults to monitor for side effects like injection-site reactions, fever, or fatigue. The study compares this experimental vaccine against an existing pneumonia vaccine to see how well people tolerate it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0004)
RECRUITINGSpringfield, Missouri, 65802, United States
Contact Phone: •••-•••-••••
-
QPS-MRA, LLC-Early Phase ( Site 0002)
RECRUITINGSouth Miami, Florida, 33143, United States
Contact Phone: •••-•••-••••
-
University of Texas Medical Branch ( Site 0001)
RECRUITINGGalveston, Texas, 77555-1115, United States
Contact Phone: •••-•••-••••
-
Velocity Clinical Research, Hallandale Beach ( Site 0003)
RECRUITINGHallandale, Florida, 33009, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.